Memantine, a glutamate NMDA receptor antagonist is approved for use as asymptomatic treatment in moderate to severe dementia due to Alzheimer’sdisease and can be used alone or added to cholinesterase inhibitors.128 We were interested in the potential utility of memantine inpost-stroke cognitive impairment and we specified outcomes relating tocognitive decline, BPSD, caregiver burden and AE. This evidence concerns the gene BCHE and Cognitive impairment.